SGLT2 inhibitors (dapagliflozin, canagliflozin, empagliflozin) increase renal uric acid excretion and have been shown in recent trials to lower serum urate, reduce gout risk in diabetics, and provide cardiovascular and renal benefits [39]. This evidence concerns the gene SLC5A2 and gout.